Drug Trial Radar · NCT06351631
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
May 23, 2024
Primary completion
Dec 4, 2034
Study completion Dec 4, 2034
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Apr 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response. No hypothesis testing will be conducted in this study.
Conditions
- Thrombocythemia, Essential
- Primary Myelofibrosis
- Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
- Polycythemia Vera
Interventions
BomedemstatDrug
10, 15, 20, and 50 mg oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with one or more adverse events (AEs)Time frame: Up to ~10 years
- Percentage of participants who discontinued study treatment due to an AETime frame: Up to ~10 years
Locations
21 sites in 6 countries. Site status is shown where the registry gives one.
University of Michigan ( Site 6000)
Ann Arbor, Michigan · Recruiting
DUHS Duke Blood Cancer Center ( Site 6005)
Durham, North Carolina · Recruiting
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
Columbus, Ohio · Recruiting
UPMC Hillman Cancer Center ( Site 6004)
Pittsburgh, Pennsylvania · Recruiting
Royal Prince Alfred Hospital ( Site 1003)
Camperdown, New South Wales, Australia · Recruiting
Royal North Shore Hospital ( Site 1001)
St Leonards, New South Wales, Australia · Recruiting
Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
Buderim, Queensland, Australia · Recruiting
Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
Southport, Queensland, Australia · Recruiting
Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
Adelaide, South Australia, Australia · Recruiting
Monash Health ( Site 1004)
Clayton, Victoria, Australia · Recruiting
Queen Mary Hospital ( Site 1601)
Hksar, Hong Kong · Active not recruiting
Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
Alessandria, Italy · Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
Bologna, Italy · Recruiting
Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
Varese, Italy · Recruiting
Azienda Ospedaliera Universitaria Careggi ( Site 2700)
Florence, Tuscany, Italy · Recruiting
North Shore Hospital-Department of Haematology ( Site 1401)
Auckland, New Zealand · Active not recruiting
Aotearoa Clinical Trials ( Site 1400)
Auckland, New Zealand · Active not recruiting
Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
London, Hammersmith and Fulham, United Kingdom · Recruiting
Boston Pilgrim Hospital ( Site 3403)
Boston, Lincolnshire, United Kingdom · Recruiting
University College London Hospital ( Site 3400)
London, London, City of, United Kingdom · Recruiting
Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
London, London, City of, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.